Thank you to our elected leaders and all of the AZBio Members who joined us to honor them at Trailblazers 2017!
During our Trailblazers panel discussion, Dr. Andy Theodorou shared with us the important opportunity for each of us to become part of the All of Us research program. You can help shape the future of medicine. To learn how, click here
AZBio Member News
Phoenix, AZ.—Beacon Biomedical Inc., a medical diagnostic development company and CLIA laboratory based in Phoenix Arizona, today announced the launch of BeScreened™-CRC, a blood-based laboratory developed test (LDT) for colorectal cancer (CRC) screening that is 95% accurate at detecting CRC in adults ages 50-75 years of age with an overall 91% sensitivity and 86% specificity for CRC stages I-IV. Preliminary study findings also indicate a greater than 60% sensitivity for detecting precancerous polyps (advanced adenomas).
Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment (COA) qualification from the US Food and Drug Administration (FDA) for the Symptoms of Major Depressive Disorder Scale (SMDDS). This qualification of the SMDDSfor exploratory use represents a major milestone for the PRO Consortium and specifically for the Depression Working Group, and is the culmination of a multi-year collaboration between FDA’s Center for Drug Evaluation and Research (CDER) and the PRO Consortium.
$5.13 million National Cancer Institute grant funds research to help identify patients before the disease causes symptoms or spreads
With funding from the U.S. Department of Agriculture, researchers will develop new disinfectants, grow new breeds of melons, and educate farmers, retailers and consumers on safe melon production practices.
Medical imaging technology like MRIs and CT scans have revolutionized the way patients are diagnosed with injuries and disease by enabling doctors to non-invasively look beneath the patient’s skin.